Nadia Harbeck, MD, PhD, from the University of Münster, recently conducted a primary outcome analysis of the multicenter randomized PreCycle trial, evaluating the impact of CANKADO PRO-React eHealth support on patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy.
The primary objective of the study was to assess the effect of eHealth support on the time to deterioration of quality of life in these patients.
The PreCycle trial included a total of 234 patients who were randomly assigned to either the intervention group or the control group.
The intervention group received the CANKADO PRO-React eHealth support in addition to their standard care, while the control group received standard care alone.
The eHealth support provided by CANKADO PRO-React included personalized patient education, medication reminders, symptom tracking, and a communication platform for patients and healthcare providers.
The primary outcome measure of the study was the time to deterioration of quality of life, which was assessed using the EORTC QLQ-C30 questionnaire.
The questionnaire evaluated various aspects of quality of life, including physical, emotional, and social functioning, as well as symptom burden.
The results of the analysis showed that patients in the intervention group had a significantly longer time to deterioration of quality of life compared to those in the control group.
The findings of this analysis are particularly relevant for patients with HR+ HER2- metastatic breast cancer, as maintaining a good quality of life is crucial in managing their disease.
The CANKADO PRO-React eHealth support proved to be effective in delaying the deterioration of quality of life, which can have a positive impact on the overall well-being and treatment outcomes of these patients.
Dr. Harbeck’s study contributes to the growing body of evidence supporting the use of eHealth interventions in oncology care.
The personalized patient education and medication reminders provided by CANKADO PRO-React can help patients adhere to their treatment plans, while the symptom tracking and communication platform facilitate timely interventions and support from healthcare providers.
By improving patient self-management and enhancing communication between patients and healthcare professionals, eHealth interventions like CANKADO PRO-React have the potential to improve treatment outcomes and quality of life in patients with metastatic breast cancer.
In conclusion, the primary outcome analysis of the PreCycle trial led by Dr. Nadia Harbeck demonstrates that the use of CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy is associated with a longer time to deterioration of quality of life.
These findings underscore the importance of incorporating eHealth interventions into routine oncology care to enhance patient outcomes and well-being.